Efficacy News and Research

RSS

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs, according to a review published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

15 Sep 2015

Genetics and race influence patients' response to anticancer drug treatments

A new study published in Pharmacogenomics suggests that a person's response to anticancer drug treatments is strongly related to their genetic ancestry. Pharmacogenomics is published by Future Science Group.

14 Sep 2015

Genetic mutations in deadly Ebola virus appear to block antibody-based treatments

Genetic mutations called "escape variants" in the deadly Ebola virus appear to block the ability of antibody-based treatments to ward off infection, according to a team of U.S. Army scientists and collaborators. Their findings, published online this week in the journal Cell Reports, have implications for the continued development of therapeutics to treat Ebola virus disease, which has claimed the lives of over 11,000 people in West Africa since last year.

14 Sep 2015

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.

11 Sep 2015

Modified Story Memory Technique improves memory in adults with moderate to severe TBI

Kessler Foundation researchers published results of a randomized clinical trial (RCT) of a cognitive intervention to improve learning and memory in individuals with traumatic brain injury (TBI) - the TBI-MEM trial.

11 Sep 2015

BioDelivery Sciences and Endo present Phase 2 data on buprenorphine HCl buccal film in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc. today presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI’s patented BioErodible MucoAdhesive (BEMA) drug delivery technology.

11 Sep 2015

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Scientists at the University of California, San Diego School of Medicine have elucidated a genetic interaction that may prove key to the development and progression of glaucoma, a blinding neurodegenerative disease that affects tens of millions of people worldwide and is a leading cause of irreversible blindness.

11 Sep 2015

Race, ethnicity may influence physician-patient decision-making process

Racial and ethnic inequalities in medical care are widely documented in literature. However, variations in Americans' experiences with healthcare, specifically regarding physician-patient communication and shared decision-making about treatment plans, are not well understood.

10 Sep 2015

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.

10 Sep 2015

New trial results show efficacy of novel enzyme-replacement therapy for genetic lipid disorder

Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies.

10 Sep 2015

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome that causes major disruption in several areas of life for many women. Many treatment options have been proposed, but which are most effective? A comprehensive review of the evidence, including specific treatment guidelines, is presented in the September Journal of Psychiatric Practice, published by Wolters Kluwer.

9 Sep 2015

Myriad Genetics presents two posters on myPlan Lung Cancer prognostic test at WCLC 2015

Myriad Genetics, Inc. today presented two posters on its myPlan Lung Cancer prognostic test at the International Association for the Study of Lung Cancer 16th World Conference on Lung Cancer being held in Denver, Colo.

9 Sep 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

9 Sep 2015

New molecule shows efficacy in inhibiting inflammation, preventing premature delivery in murine models

Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.

9 Sep 2015

Gallup-Palmer report: 57% of U.S. adults use chiropractic care for back or neck pain

According to a new Gallup-Palmer report that tested public assumptions about chiropractic care, 57 percent of U.S. adults are likely to visit a doctor of chiropractic (DC) if they experience back or neck pain.

9 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proof-of-concept ("POC") trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer ("NSCLC") in China.

4 Sep 2015

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Allergan plc, a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

4 Sep 2015

Valerion announces positive results from non-clinical pilot study of VAL-1221 for treatment of Pompe disease

Valerion Therapeutics, LLC yesterday announced positive results from a non-clinical "proof of concept" pilot study for a novel humanized antibody and acid alpha glucosidase (GAA) fusion candidate for the treatment of Pompe disease.

3 Sep 2015

Efficacy News and Research

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Genetics and race influence patients' response to anticancer drug treatments

Genetic mutations in deadly Ebola virus appear to block antibody-based treatments

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Modified Story Memory Technique improves memory in adults with moderate to severe TBI

BioDelivery Sciences and Endo present Phase 2 data on buprenorphine HCl buccal film in patients with chronic pain

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Race, ethnicity may influence physician-patient decision-making process

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

New trial results show efficacy of novel enzyme-replacement therapy for genetic lipid disorder

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Myriad Genetics presents two posters on myPlan Lung Cancer prognostic test at WCLC 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

New molecule shows efficacy in inhibiting inflammation, preventing premature delivery in murine models

Gallup-Palmer report: 57% of U.S. adults use chiropractic care for back or neck pain

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

AstraZeneca presents lung cancer research data at WCLC 2015

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Valerion announces positive results from non-clinical pilot study of VAL-1221 for treatment of Pompe disease

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News